Momelotinib
Brand names: Ojjaara · Active ingredient: Momelotinib Dihydrochloride Monohydrate
In short: OJJAARA is indicated for the treatment of intermediate or high‑risk myelofibrosis (MF), including primary MF or secondary MF [post‑polycythemia vera (PV) and post‑essential thrombocythemia (ET)], in adults with anemia.
What is Momelotinib used for?
OJJAARA is indicated for the treatment of intermediate or high‑risk myelofibrosis (MF), including primary MF or secondary MF [post‑polycythemia vera (PV) and post‑essential thrombocythemia (ET)], in adults with anemia.
Momelotinib dosage
The recommended dosage of OJJAARA is 200 mg orally once daily. OJJAARA may be taken with or without food.
Swallow OJJAARA tablets whole. Do not cut, crush, or chew tablets.
If a dose of OJJAARA is missed, the next scheduled dose should be taken the following day.
Obtain the following blood tests prior to starting treatment with OJJAARA, periodically during treatment, and as clinically indicated:
•Complete blood count (CBC) with platelets
•Hepatic panel
The recommended starting dosage in patients with severe hepatic impairment (Child‑Pugh Class C) is 150 mg orally once daily . No dose adjustment is recommended for patients with mild or moderate hepatic impairment.
Manage hematologic and non‑hematologic adverse reactions as described in Table 1.
ALT = alanine transaminase; AST = aspartate transaminase; ULN = upper limit of normal.
a Reinitiate or escalate treatment up to starting dosage as clinically appropriate.
b May reinitiate treatment at 100 mg if previously dosed at 100 mg.
c If baseline >2 × ULN.
d If baseline >1.5 × ULN.
e Graded using the National Cancer Institute Common Terminology Criteria for Adverse Events per (CTCAE).
Thrombocytopenia | Dose Modificationa
Baseline Platelet Count | Platelet Count
≥100 × 109/L | 20 × 109/L to <50 × 109/L | Reduce daily dose by 50 mg from the last given dose.
<20 × 109/L | Interrupt treatment until platelets recover to 50 × 109/L.
Restart OJJAARA at a daily dose of 50 mg below the last given dose.b
≥50 × 109/L to <100 × 109/L | <20 × 109/L | Interrupt treatment until platelets recover to 50 × 109/L.
Restart OJJAARA at a daily dose of 50 mg below the last given dose.b
<50 × 109/L | <20 × 109/L | Interrupt treatment until platelets recover to baseline.
Restart OJJAARA at a daily dose of 50 mg below the last given dose.b
Neutropenia | Dose Modificationa
Absolute neutrophil count (ANC) <0.5 × 109/L | Interrupt treatment until ANC ≥0.75 × 109/L.
Restart OJJAARA at a daily dose of 50 mg below the last given dose.b
Hepatotoxicity
(unless other apparent causes) | Dose Modificationa
ALT and/or AST >5 × ULN (or >5 × baseline, if baseline is abnormal) and/or total bilirubin >2 × ULN (or >2 × baseline, if baseline is abnormal) | Interrupt treatment until AST and ALT ≤2 × ULN or baselinec and total bilirubin ≤1.5 × ULN or baseline.d
Restart OJJAARA at a daily dose of 50 mg below the last given dose.b
If reoccurrence of ALT or AST elevations >5 × ULN, permanently discontinue OJJAARA.
Other Non‑Hematologic | Dose Modificationa
Grade 3 or highere | Interrupt treatment until the toxicity resolves to Grade 1 or lower (or baseline).
Restart OJJAARA at a daily dose of 50 mg below the last given dose.b
Discontinue OJJAARA in patients unable to tolerate 100 mg once daily.
How to take Momelotinib — instructions & advice from the label
Advise the patient to read the FDA approved patient labeling (Patient Information).
Infections
Inform patients that OJJAARA can increase the risk of infections (including COVID‑19) and instruct them to promptly report to their healthcare provider any signs and symptoms of infection .
Thrombocytopenia and Neutropenia
Inform patients that OJJAARA can cause thrombocytopenia and neutropenia, and of the need to monitor CBC, including platelet and neutrophil counts, before and during treatment. Advise patients to observe for and report any bleeding to their healthcare provider .
Hepatotoxicity
Inform patients that OJJAARA can cause hepatotoxicity, and of the need to monitor liver blood tests before and during treatment .
Severe Cutaneous Adverse Reactions (SCARs)
Inform patients that SCARs have been observed in some patients treated with OJJAARA and instruct them to promptly report any signs and symptoms of SCARs to their healthcare provider . …
Warnings & precautions
Do not take this medicine if: None.
Serious (including fatal) infections (e.g., bacterial and viral, including COVID‑19) occurred in 13% of patients treated with OJJAARA. Infections regardless of grade occurred in 38% of patients treated with OJJAARA . Delay starting therapy with OJJAARA until active infections have resolved. Monitor patients receiving OJJAARA for signs and symptoms of infection and initiate appropriate treatment promptly.
Hepatitis B Reactivation
Hepatitis B viral load (HBV‑DNA titer) increases, with or without associated elevations in alanine transaminase (ALT) or aspartate transaminase (AST), have been reported in patients with chronic hepatitis B virus (HBV) infection taking Janus Kinase (JAK) inhibitors, including OJJAARA. The effect of OJJAARA on viral replication in patients with chronic HBV infection is unknown. In patients with HBV infections, check hepatitis B serologies prior to starting OJJAARA. If HBsAg and/or anti‑HBc antibody is positive, consider consultation with a hepatologist regarding monitoring for reactivation versus prophylactic hepatitis B therapy. Patients with chronic HBV infection who receive OJJAARA should have their chronic HBV infection treated and monitored according to clinical HBV guidelines.
OJJAARA can cause thrombocytopenia and neutropenia .
New or worsening thrombocytopenia, with platelet count less than 50 × 109/L, was observed in 20% of patients treated with OJJAARA. Eight percent of patients treated with OJJAARA had baseline platelet counts less than 50 × 109/L.
Severe neutropenia, absolute neutrophil count (ANC) less than 0.5 × 109/L, was observed in 2% of patients treated with OJJAARA.
Assess CBCs, including platelet and neutrophil counts, before initiating treatment and periodically during treatment as clinically indicated. Interrupt dosing or reduce the dose for thrombocytopenia or neutropenia . …
Momelotinib side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
•Risk of Infections and Hepatitis B Reactivation
•Thrombocytopenia and Neutropenia
•Hepatotoxicity
•Severe Cutaneous Adverse Reactions
•Major Adverse Cardiovascular Events
•Thrombosis
•Malignancies
•Symptom Exacerbation Following Interruption or Discontinuation of Treatment
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of OJJAARA was evaluated in 215 patients in 2 clinical trials (MOMENTUM and SIMPLIFY‑1 anemic subgroup [hemoglobin (Hb) <10 g/dL]) .
MOMENTUM
Patients in the MOMENTUM trial had been previously treated with a JAK inhibitor and were randomly assigned 2:1 to receive double‑blind OJJAARA 200 mg orally once daily (n = 130) or danazol 300 mg orally twice daily (n = 65) for 24 weeks, after which they were eligible to receive open‑label OJJAARA in an extended treatment phase. Among patients who received OJJAARA, 72% were exposed for 24 weeks or longer and 52% were exposed for 48 weeks or longer . …
Drug interactions
Organic Anion Transporting Polypeptide (OATP)1B1/B3 Inhibitors
Momelotinib is an OATP1B1/B3 substrate. Concomitant use with an OATP1B1/B3 inhibitor increases momelotinib maximal concentrations (Cmax) and area under the concentration‑time curve (AUC), which may increase the risk of adverse reactions with OJJAARA . Monitor patients concomitantly receiving an OATP1B1/B3 inhibitor for adverse reactions and consider OJJAARA dose modifications .
Breast Cancer Resistance Protein (BCRP) Substrates
Momelotinib is a BCRP inhibitor. OJJAARA may increase exposure of BCRP substrates, which may increase the risk of BCRP substrate adverse reactions . When administered concomitantly with OJJAARA, initiate rosuvastatin (BCRP substrate) at 5 mg and do not increase to more than 10 mg once daily. Dose adjustment of other BCRP substrates may also be needed. Follow approved product information recommendations for other BCRP substrates.
About this medicine
OJJAARA contains momelotinib dihydrochloride monohydrate, which is a kinase inhibitor with the chemical name N‑(Cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide dihydrochloride monohydrate. It has a molecular formula of C23H22N6O2
●2HCl●H2O, molecular weight of 505.40 and the following structural formula:
Momelotinib dihydrochloride monohydrate is a light yellow to brown to reddish-brown solid and is slightly soluble in water and insoluble in aqueous buffers across a pH range of 2.1 to 9. Momelotinib free base has a molecular formula of C23H22N6O2 and a molecular weight of 414.47.
OJJAARA (momelotinib) tablets are for oral administration. Each tablet contains 100 mg, 150 mg, or 200 mg of momelotinib, which is equivalent to 121.94 mg, 182.91 mg, or 243.88 mg, respectively, of momelotinib dihydrochloride monohydrate as the active ingredient. The core of each tablet contains the following inactive ingredients: lactose monohydrate, magnesium stearate, microcrystalline cellulose, propyl gallate, silicon dioxide, and sodium starch glycolate. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 4a672fd1-eb7b-4aa9-9b23-845e4b5dc400. Read the full official label on DailyMed.